Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NBN
REST API REST API
Homo sapiens
NBN is differentially expressed in 354 experiments: 142 organism parts: ovary, heart, ... (140 more);, 239 disease states: normal, breast carcinoma, ... (237 more);, 114 cell types 461 cell lines 50 compound treatments and 82 other conditions.
Synonyms AT-V2, AT-V1, NBS1, NBS, ATV
Orthologs NBN (Gallus gallus)   Nbn (Mus musculus)   Nbn (Rattus norvegicus)   ENSCING00000002421 (Ciona intestinalis)   nbn (Danio rerio)   NBN (Bos taurus)   nbs (Drosophila melanogaster)   nbn (Xenopus laevis)   NBN (Canis familiaris)   (Compare orthologs)
Gene Ontology Term telomere maintenance, DNA damage checkpoint, double-strand break repair via homologous recombination, protein binding, apoptosis, DNA repair, cell proliferation, damaged DNA binding, Mre11 complex, intracellular, meiosis, positive regulation of cell proliferation, protein N-terminus binding, replication fork, cell cycle arrest, double-strand break repair, transcription factor binding, DNA duplex unwinding, nuclear chromosome, telomeric region, DNA damage response, signal transduction by p53 class mediator, cell cycle, nucleus, ATP-dependent DNA helicase activity, response to drug, chromosome, nucleoplasm, nucleolus, nuclear inclusion body, regulation of fibroblast proliferation, in utero embryonic development, blastocyst growth, regulation of DNA-dependent DNA replication initiation, mitotic cell cycle G2/M transition DNA damage checkpoint, neuromuscular process controlling balance, negative regulation of neuron differentiation, G2/M transition checkpoint, isotype switching, positive regulation of kinase activity, positive regulation of protein autophosphorylation, mitotic cell cycle G1/S transition checkpoint
InterPro Term Nibrin_met, FHA_dom, BRCT, DNA-repair_Nbs1_C
Gene-Disease Assocation APLASTIC ANEMIA, BREAST CANCER, NIJMEGEN BREAKAGE SYNDROME
UniProt Accession O60934, E5RGU1, E5RGR7, E5RGN7, E2QRP0, F5H3R2
Search EB-eye ENSG00000104320
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-GEOD-8167, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (47 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081, E-GEOD-5823
SW480
1
3
E-MEXP-1014, E-GEOD-18005, E-GEOD-2509, E-MTAB-37
SNU1
2
E-MTAB-37, E-GEOD-15460
A549
2
E-GEOD-3202, E-GEOD-6013
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MOLT4
2
E-MTAB-62, E-MTAB-37
455 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (49 experiments)

Factor Value U/D Experiments
whole blood
2
E-MTAB-25, E-GEOD-3026
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
adipocyte
2
E-AFMX-5, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
neutrophil
2
E-GEOD-12662, E-GEOD-3982
108 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-GEOD-16363, E-MTAB-62, ... (70 experiments)

Factor Value U/D Experiments
myeloma
3
E-MTAB-62, E-MTAB-372, E-MTAB-37
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
neuroblastoma
2
E-MTAB-62, E-MTAB-37
rhabdomyosarcoma
2
E-MTAB-37, E-MTAB-62
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
acute promyelocytic leukemia
1
2
E-MTAB-62, E-GEOD-995, E-GEOD-96
233 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5542, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (38 experiments)

Factor Value U/D Experiments
lipopolysaccharide
4
E-MEXP-1958, E-TABM-868, E-GEOD-3720, E-GEOD-2706
none
6
9
E-GEOD-5824, E-MEXP-1958, E-MEXP-1230, E-TABM-868, E-GEOD-412, ... (15 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
selenium
1
E-MEXP-1327
unknown
1
E-GEOD-7307
granulocyte-colony stimulating factor
1
E-GEOD-7400
44 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1140, E-GEOD-22513, ... (10 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-GEOD-2509, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-22593, E-GEOD-20115, E-GEOD-18005, E-TABM-868, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, E-TABM-440, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-974, E-MEXP-2069, ... (40 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (9 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-19703, E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-22541, E-GEOD-7307, E-GEOD-1295

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-22152, E-GEOD-21909, E-GEOD-19246, ... (10 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.312 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM